8-K: InMed Pharmaceuticals Faces Nasdaq Equity Warning

InMed Pharmaceuticals received a Nasdaq notice for failing to meet minimum shareholder equity requirements, but anticipates regaining compliance through its pending merger with Mentari Therapeutics.

Summary

• InMed Pharmaceuticals received a notification from Nasdaq indicating non-compliance with the minimum shareholders' equity requirement of $2,500,000, as its equity was reported at $1,075,007 in its fiscal year 2026 10-K.
• This shortfall is primarily attributed to transaction-related expenses from the proposed merger with Mentari Therapeutics, costs from winding down its subsidiary BayMedica, increased G&A expenses, impairment charges, and operating losses.
• The company expects the completion of the merger with Mentari, which includes a significant pre-closing financing of approximately $490 million, to resolve the equity deficiency and restore compliance with Nasdaq listing rules.
• Nasdaq has granted InMed 45 days to submit a compliance plan, with a potential extension of up to 180 days to demonstrate compliance if the plan is accepted.
• The notice does not immediately impact the trading of InMed's common shares, which will continue to be listed under the symbol 'INM' on The Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the Nasdaq non-compliance notice, although the pending merger offers a potential path to resolution.

Positives

• The pending merger with Mentari Therapeutics is expected to provide approximately $490 million in gross proceeds, which should resolve the shareholder equity deficiency.
• The company's closing share price on September 18, 2026, increased by approximately 99.8% ($0.68) compared to the price before the merger announcement, indicating positive market sentiment towards the transaction.
• The merger is anticipated to close in the fourth quarter of 2026, subject to shareholder approval.
• The Nasdaq notice has no immediate impact on the listing or trading of InMed's common shares.

Negatives

• InMed Pharmaceuticals is currently not in compliance with Nasdaq Listing Rule 5550(b)(1), requiring a minimum of $2,500,000 in shareholders' equity.
• The company reported shareholders' equity of $1,075,007 as of June 30, 2026.
• The decline in equity is due to significant transaction-related expenses, costs from winding down BayMedica, increased general and administrative expenses, impairment charges, and ongoing operating losses.

Risks

• Uncertainty regarding the acceptance of the compliance plan by Nasdaq and the ability to regain compliance within the stipulated timelines.
• Potential delisting if compliance is not achieved, which could adversely affect share liquidity, trading price, and the ability to obtain financing.
• Uncertainty regarding the closing of the merger with Mentari Therapeutics on the expected timeline or at all.
• The risk that the expected benefits of the merger and the anticipated gross proceeds from the pre-closing financing may not be realized.
• The possibility that the merger's closing may not result in regaining compliance with Nasdaq's minimum shareholders' equity requirement.
• Potential for changes in business strategy or plans that could impact future performance.
• The risk that any appeal of a delisting determination to a Nasdaq Hearings Panel may not be successful.

Future Outlook

The company expects the closing of the merger with Mentari Therapeutics to result in regaining compliance with Nasdaq's minimum shareholders' equity requirement. The merger is anticipated to close in the fourth quarter of 2026, subject to shareholder approval and other conditions. The company intends to submit a plan to Nasdaq to regain compliance within the specified deadlines.

Management Comments

• The Company expects that closing of the transactions contemplated by the Merger Agreement will result in the Company regaining compliance with The Nasdaq Capital Markets minimum shareholders equity requirement.
• The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq, including continuing to pursue the consummation of the Merger.
• The Company intends to submit the compliance plan by the Nasdaq deadline.

Industry Context

StockSavvy.ai notes that Nasdaq listing compliance issues, particularly concerning minimum equity, are not uncommon for smaller biotechnology and pharmaceutical companies navigating complex development cycles and significant R&D expenditures. The reliance on a merger to rectify such issues highlights the strategic importance of M&A activity in the sector for capital infusion and survival.

Stakeholder Impact

• Shareholders: Potential for share price volatility due to the Nasdaq compliance issue and the uncertainty of delisting. However, the pending merger and associated capital raise could be viewed positively if successful.
• Creditors: The company's ability to continue operations and meet obligations may be indirectly affected by its Nasdaq listing status and the success of the merger.
• Employees: Continued listing on Nasdaq is important for employee morale and the company's ability to attract and retain talent.

Next Steps

• Submit a plan to Nasdaq to regain compliance with the minimum shareholders' equity requirement by November 2, 2026.
• Evidence compliance with the minimum shareholders' equity standard within up to 180 days from September 16, 2026, if the plan is accepted.
• Seek shareholder approval for the merger with Mentari Therapeutics.
• Complete the merger with Mentari Therapeutics, expected in the fourth quarter of 2026.
• Prepare and file a definitive proxy statement/prospectus and management information circular related to the merger.

Key Dates

Recommendation

The current situation presents a mixed outlook. While the Nasdaq non-compliance notice is a negative development, the pending merger with Mentari Therapeutics, which is expected to inject significant capital and resolve the equity issue, offers a strong potential positive catalyst. The market has reacted positively to the merger announcement, as evidenced by the share price increase. However, the uncertainty surrounding the merger's closing and Nasdaq's plan acceptance warrants a cautious 'hold' recommendation until these key events are resolved.

Keywords

Nasdaq compliance, Shareholders equity, Merger, Mentari Therapeutics, Delisting risk, Pharmaceuticals, Capital raise, Listing requirements